KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Free Cash Flow (2016 - 2025)

Emergent BioSolutions' Free Cash Flow history spans 16 years, with the latest figure at $65.7 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 181.92% year-over-year to $65.7 million; the TTM value through Dec 2025 reached $156.8 million, up 176.06%, while the annual FY2025 figure was $156.8 million, 176.06% up from the prior year.
  • Free Cash Flow reached $65.7 million in Q4 2025 per EBS's latest filing, up from -$1.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $167.5 million in Q3 2024 to a low of -$191.8 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$11.3 million, with a median of -$12.2 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: soared 601.18% in 2021, then plummeted 1090.62% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at $124.6 million in 2021, then plummeted by 213.08% to -$140.9 million in 2022, then soared by 114.69% to $20.7 million in 2023, then crashed by 487.44% to -$80.2 million in 2024, then surged by 181.92% to $65.7 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Free Cash Flow are $65.7 million (Q4 2025), -$1.9 million (Q3 2025), and $107.8 million (Q2 2025).